RGA 2025-26: Record EPS $17.69 (+65%), ROE 15.7%, Equitable $160-170M
Thesis
Reinsurance Group of America (NYSE: RGA) closed FY25 (December year-end) with a record sweep: revenue $22.79B (+3.4% YoY), operating income $1.54B (+57%), net income $1.18B (+65%), and diluted EPS $17.69 (+65% from $10.73). Adjusted operating return on equity hit 15.7% — exceeding RGA's 13-15% intermediate-term target and sustaining above the top end for the full year. Q4 operating EPS was $7.75, the second consecutive record quarter. Total capital deployed into in-force transactions reached $2.5B in FY25; value of in-force business margins increased 18% over FY25. Excess capital at year-end: $2.7B.
The FY25 story has three drivers: (1) Equitable transaction closed Q3 2025, contributing the first ~$70M pretax income in H2 2025 (ramps to $160-170M in 2026 and ~$200M by 2027); (2) in-force management actions generating $95M favorable impact in Q4 alone (+$95M embedded upside from repricing existing blocks); (3) variable investment income outperformance from the alternatives portfolio. Underlying traditional premium growth was +11% on constant-currency basis year-to-date through Q2 2025.
The FY25-26 thesis rests on five legs:
-
Equitable transaction ramp ($160-170M pretax 2026 → $200M 2027): Closed mid-2025, the Equitable life insurance block is RGA's largest single in-force management action in recent history. It contributed
$70M H2 2025; management guides $160-170M for full-year 2026 (+$95-100M incremental) and ~$200M per year by 2027. This is a multi-year earnings ramp from a single deal. -
Creation Re flywheel driving new business: RGA's proprietary Creation Re product development engine — where RGA creates products with carriers rather than just reinsuring existing blocks — has generated >50% of new business over the past two years. Strong new treaties in Asia Traditional (Hong Kong, simplified issue critical illness), UK Pension Risk Transfer (PRT), and US traditional business all pulled through the flywheel.
-
In-force management actions as recurring lever: $95M favorable Q4 impact; 16% increase in value of in-force business margins over three quarters. Management notes timing of these actions is "unpredictable" but the pipeline is ongoing. Each action — repricing, restructuring, risk transfer — creates multi-year earnings improvement.
-
Multi-regional diversification with ROE above target: EMEA longevity + Financial Solutions growing; APAC Traditional favorable multi-quarter; Canada steady; US recovering from group claims volatility. Each region operates independently, providing earnings diversification across underwriting cycles.
-
Capital deployment optionality ($2.7B excess): $2.7B of excess capital at year-end; $1.5B targeted for in-force transactions in 2026; $400M earmarked to reduce financial leverage. Buybacks reinstated in Q3 FY25 ($174M FY25 vs $27M FY24). Dividend + buyback target 20-30% of after-tax operating earnings.
The risks are mortality/morbidity experience volatility (group healthcare, large claims), variable investment income dependence, FX headwinds on international segments, and execution on Equitable integration — but RGA's status as the world's premier life and health reinsurer, its FY25 ROE of 15.7% well above target, and the Equitable earnings ramp position it for sustained double-digit EPS growth into 2027.
FY25 Numbers vs FY24 (Annual, USD)
| Metric | FY24 | FY25 | Δ |
|---|---|---|---|
| Revenue | $22.04B | $22.79B | +3.4% |
| Operating income | $980M | $1.54B | +57% |
| Net income | $717M | $1.18B | +65% |
| EPS diluted | $10.73 | $17.69 | +65% |
| Adj operating ROE | ~12-13% | 15.7% | >target |
| Free cash flow | $9.37B | $4.09B | n/a* |
| Total debt | $5.04B | $5.71B | +13% |
| Buyback | $27M | $174M | +544% |
*FCF swing FY24→FY25 reflects working capital + reinsurance premium timing — common in reinsurance; operating earnings are the primary profitability metric.
Quarterly trajectory (EPS): Q1 $4.27 → Q2 $2.70 → Q3 $3.78 → Q4 $6.97. The Q4 acceleration (to $6.97 GAAP; $7.75 operating) reflects: $95M in-force management actions, strong variable investment income from alternatives, and Equitable H2 contribution.
Segment Breakdown
U.S. and Latin America Traditional
The largest segment by premium; individual life + group business.
- Q4 FY25: Favorable from in-force management actions + strong variable investment income; partially offset by unfavorable group claims experience (note: group healthcare is repricing by 2026 — short-term headwind, multi-year positive)
- Q3 FY25: Modestly unfavorable claims experience offset by favorable in-force management actions
- Q2 FY25: Unfavorable large claims volatility + group healthcare excess (noted as short-term)
- Q1 FY25: Favorable individual life — lower-than-expected large claims
US Traditional is the base. Q4 favorable outcome despite Q2/Q3 turbulence demonstrates the in-force management action lever — each repricing event resets the earnings trajectory.
U.S. Financial Solutions (Equitable Transaction)
The fastest-growing earnings contributor.
- Equitable transaction: Closed Q3 2025 (effective Q2 for accounting); ~$70M pretax income H2 2025
- FY2026 guide: $160-170M pretax income (management consistent guidance across Q1/Q2/Q3/Q4 calls)
- FY2027 guide: ~$200M per year
- Q4 FY25: Earnings consistent with $60-70M H2 guidance
- Underlying: Variable investment income driver; higher investment yields benefit the Financial Solutions book
The Equitable earnings ramp is the single clearest multi-year accretion item on RGA's P&L. $70M (H2 2025) → $160-170M (2026) → $200M (2027) on a constant capital base is ~+$100M of incremental pretax income added per year for two years straight.
EMEA (Traditional + Financial Solutions)
The global longevity + structured reinsurance engine.
- Q4 FY25: Traditional largely in line; Financial Solutions favorable longevity experience + strong growth
- Q3 FY25: Favorable underwriting margins (Traditional); favorable longevity + growth (Financial Solutions)
- UK PRT (Pension Risk Transfer): Strong UK PRT sales expected; RGA is a market leader with multiple successful transactions
- EMEA Financial Solutions: Above expectations in multiple quarters; higher variable investment income + higher margins
EMEA is RGA's longevity franchise — one of the world's most complex and scalable reinsurance niches, underpinned by UK pension de-risking (£50B+ annual PRT market) and continental European life reinsurance growth.
Asia Pacific (Traditional + Financial Solutions)
Consistent growth contributor.
- Q4 FY25: Good quarter with favorable underwriting margin + growth; Financial Solutions in line
- Q3 FY25: Another good quarter with favorable claims + ongoing growth
- New treaties: Hong Kong + simplified issue critical illness (Creation Re initiative); Japan block transactions (Q1 FY25)
- Q1 FY25: Strong new treaty activity driven by Creation Re product development
APAC is the long-run growth engine. Life insurance penetration in Southeast Asia, South Korea, Taiwan, and China remains well below Western markets — multi-decade runway for RGA's traditional life reinsurance and Creation Re product development model.
Canada Traditional
Steady, modest contributor; generally favorable with periodic group noise.
FY26 Framework
Management's explicit 2026 framework (from Q4 FY25 call, Feb 2026):
- EPS growth target: 8-10% annually (intermediate-term)
- ROE target: 13-15% (currently running at 15.7% — above top end)
- Equitable contribution: $160-170M pretax in 2026 (vs ~$70M H2 2025)
- Variable investment income: Expected at 7% of investment base in 2026
- In-force management actions: Projected to have more limited financial impact in 2026 vs 2025 (timing unpredictable; $95M Q4 2025 was outsized)
- Capital deployment: ~$1.5B into in-force transactions in 2026 (vs $2.5B in FY25)
- Leverage reduction: $400M excess capital earmarked to reduce financial leverage
- Shareholder return: 20-30% of after-tax operating earnings via dividends + buybacks (intermediate-term target)
The 8-10% EPS growth target is conservative given the Equitable ramp. If Equitable contributes an incremental $95-100M pretax in 2026, and all else is stable, that alone drives ~4-5% EPS growth before any operational improvement. With EMEA + APAC growth + US repricing, the range likely skews to the top end.
Multi-Year Strategic Position
Creation Re flywheel: >50% of new business from Creation Re — a structural differentiator where RGA creates products with insurance carriers rather than simply pricing risk on existing portfolios. This drives exclusivity, deeper relationships, and better risk selection vs. pure-play commodity reinsurance.
In-force management expertise: Q4 $95M favorable impact; 18% FY25 improvement in value of in-force business margins. RGA has a dedicated actuarial + financial engineering team that systematically identifies and executes repricing + restructuring opportunities in existing in-force blocks. This is a recurring, if lumpy, earnings lever.
Balance sheet depth: $2.7B excess capital at year-end; $3.4B deployable capital as of Q2 FY25 (pre-Equitable close). Capital deployment optionality at 10-15%+ ROE threshold = multi-year EPS accretion engine.
Global diversification: Seven major segments across US, Canada, EMEA, APAC = no single market > ~40% of earnings. Claims volatility in one region is routinely offset by favorable outcomes elsewhere. FY25's US group claims headwind was offset by EMEA longevity + APAC favorable claims + variable investment income.
UK PRT market leadership: The £50B+ annual UK Pension Risk Transfer market is a multi-decade de-risking wave as defined-benefit pension schemes offload longevity risk. RGA is one of the few global reinsurers with scale in this niche.
Three-engine compounding: (1) Organic traditional premium growth (+11% constant-currency); (2) In-force management + Equitable ramp (structural margin lift on existing blocks); (3) Capital deployment into new in-force transactions at 10-15%+ ROE (each dollar deployed adds to future earnings). Together they target 8-10% annual EPS growth with ROE sustainably above the 13-15% target.
Risks
- Mortality/morbidity volatility: Large claims volatility in US individual life is inherent; unfavorable group healthcare excess experience (Q2 FY25) repricing by 2026 but near-term headwind
- Variable investment income dependence: Strong alternatives portfolio returns boosted FY25; reversion to mean in alt income could compress margins from Q4/FY25 levels
- In-force action timing unpredictability: Management explicitly notes timing is "unpredictable" — Q4's $95M could be followed by quarters with minimal impact
- Equitable execution: First full-year contribution in 2026; operational complexity of a large US individual life block
- FX headwinds: EMEA (GBP, EUR) + APAC (JPY, HKD, SGD, AUD) revenues all translated to USD; USD strength compresses reported earnings
- Group healthcare repricing lag: US group healthcare excess claims in Q2 FY25 fully repriced by 2026 — but if repricing is inadequate or the block underperforms, the issue recurs
- Capital deployment competition: As life reinsurance competition intensifies (Munich Re, Swiss Re, Hannover Re, SCOR), pricing on new in-force transactions tightens; RGA's $1.5B FY26 deployment target assumes adequate return
- Interest rate sensitivity: Asset/liability matching at scale; rapid rate moves can create duration mismatches in Financial Solutions segment
- Regulatory changes: Life insurance regulatory frameworks evolving globally (IFRS 17, Solvency II, NAIC changes); could affect capital requirements and reinsurance economics
- Concentration in Equitable: Equitable block is now a meaningful contributor; counterparty risk to Equitable Financial (AXA subsidiary)
Citations
- RGA FY25 (Q1-Q4) earnings call transcripts (drillr earning_call_summary; period_end 2025-03 / 2025-06 / 2025-09 / 2025-12; call_date 2026-02-06 for Q4)
- RGA FY25 financial statements (drillr financial_statements; period_end 2025-12 FY)
- FY24 financial statements (drillr financial_statements; period_end 2024-12 FY)
- Q4 FY25 (call 2026-02-06): Record Q4 EPS $7.75, FY 15.7% ROE, $95M in-force Q4, Equitable 2026 guide $160-170M, $400M leverage reduction
- Q3 FY25 (call 2025-10-31): Record Q3 operating EPS $6.37, $2.4B YTD capital deployed, $75M buyback, 16% in-force margins improvement
- Q2 FY25 (call 2025-08-01): Equitable close, $3.8B excess capital, Q2 $4.72 EPS, group healthcare claims
- Q1 FY25 (call 2025-05-02): $5.66 EPS, 15% ROE, Manulife deal, Creation Re >50% of new business